Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA/FDA Oligonucleotide-Based Therapeutics Conference
Session 9: Hot Topics
Session Chair(s)
Arthur A. Levin, PhD
- CSO
- Avidity Biosciences , United States
Emily Place, PhD, MPH
- Senior Consultant
- Biologics Consulting, United States
Attendees at this session will hear about novel technologies that are bridging the gap between early research and clinical development. Each is an area that holds the promise of creating a new platform for oligonucleotide therapeutics. Featured in this session are:
- A novel delivery platform using a conjugate approach
- Circular RNAs as potential therapeutics
- A novel and personalized aptamer technology in oncology
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss insights into the promise of these technologies and how these technologies have the potential for broad applications
- Explore where the oligonucleotide therapeutics field will advance in the future
Speaker(s)
AUMMUNE Therapy Driven by Effect
Irit Carmi-Levy, PhD
- Chief Scientific Officer and Vice President R&D
- Aummune, Israel
A Novel Antibody Platform for Nucleic Acid Delivery with Broad Therapeutic Potential
Chris Duke, MBA, MPH
- Cheif Operating Officer
- Gennao Bio, United States
The Therapeutic Potential of oRNA
Robert Mabry, PhD
- Chief Scientific Officer
- Orna Therapeutics, Inc. , United States
Contact us
Registration Questions?
Additional Information
Live Meeting PoliciesDiscover DIA’s Live In-Person and Live Virtual Events